| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 56 | 2025 | 301 | 11.120 |
Why?
|
| Meningioma | 43 | 2023 | 79 | 9.500 |
Why?
|
| Meningeal Neoplasms | 40 | 2023 | 73 | 7.890 |
Why?
|
| Pituitary Neoplasms | 27 | 2023 | 48 | 7.790 |
Why?
|
| Neurosurgical Procedures | 33 | 2025 | 220 | 5.710 |
Why?
|
| Craniotomy | 21 | 2023 | 61 | 4.350 |
Why?
|
| Adenoma | 14 | 2023 | 61 | 3.750 |
Why?
|
| Postoperative Complications | 28 | 2023 | 611 | 3.720 |
Why?
|
| Glioma | 13 | 2022 | 117 | 3.670 |
Why?
|
| Skull Base Neoplasms | 9 | 2023 | 21 | 3.500 |
Why?
|
| Mutation | 34 | 2024 | 847 | 3.400 |
Why?
|
| Humans | 225 | 2025 | 28097 | 3.350 |
Why?
|
| Skull Base | 14 | 2023 | 34 | 2.440 |
Why?
|
| Craniopharyngioma | 6 | 2023 | 14 | 2.380 |
Why?
|
| Glioblastoma | 15 | 2025 | 105 | 2.270 |
Why?
|
| Neoplasm Recurrence, Local | 25 | 2023 | 330 | 2.210 |
Why?
|
| Middle Aged | 85 | 2025 | 7138 | 2.180 |
Why?
|
| Neurosurgery | 8 | 2021 | 75 | 2.140 |
Why?
|
| Quality Improvement | 10 | 2023 | 115 | 2.120 |
Why?
|
| Magnetic Resonance Imaging | 25 | 2024 | 819 | 2.090 |
Why?
|
| Nasal Cavity | 5 | 2021 | 20 | 2.060 |
Why?
|
| Male | 102 | 2025 | 13491 | 2.010 |
Why?
|
| Neuroma, Acoustic | 6 | 2020 | 23 | 1.980 |
Why?
|
| Female | 109 | 2025 | 15156 | 1.980 |
Why?
|
| Adult | 72 | 2025 | 7740 | 1.920 |
Why?
|
| B7-H1 Antigen | 7 | 2022 | 38 | 1.900 |
Why?
|
| Prognosis | 25 | 2024 | 803 | 1.860 |
Why?
|
| Chordoma | 4 | 2024 | 8 | 1.840 |
Why?
|
| Aged | 60 | 2025 | 5400 | 1.720 |
Why?
|
| Endoscopy | 8 | 2023 | 56 | 1.640 |
Why?
|
| Retrospective Studies | 44 | 2025 | 2546 | 1.590 |
Why?
|
| Treatment Outcome | 33 | 2025 | 2379 | 1.560 |
Why?
|
| Chondrosarcoma | 2 | 2022 | 6 | 1.500 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 2 | 2021 | 2 | 1.480 |
Why?
|
| Nose Neoplasms | 2 | 2021 | 6 | 1.470 |
Why?
|
| DNA Methylation | 4 | 2020 | 152 | 1.420 |
Why?
|
| Brain | 8 | 2024 | 741 | 1.390 |
Why?
|
| Radiosurgery | 8 | 2025 | 84 | 1.380 |
Why?
|
| Cerebral Angiography | 6 | 2018 | 38 | 1.350 |
Why?
|
| Young Adult | 29 | 2025 | 2733 | 1.240 |
Why?
|
| Patient Readmission | 6 | 2020 | 103 | 1.190 |
Why?
|
| Central Nervous System Cysts | 2 | 2025 | 4 | 1.120 |
Why?
|
| Pineal Gland | 2 | 2025 | 3 | 1.090 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 405 | 1.080 |
Why?
|
| Skull | 2 | 2025 | 40 | 1.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 465 | 1.060 |
Why?
|
| Aged, 80 and over | 26 | 2025 | 2021 | 1.040 |
Why?
|
| Petrous Bone | 4 | 2013 | 4 | 1.010 |
Why?
|
| DNA Copy Number Variations | 6 | 2017 | 36 | 1.000 |
Why?
|
| Epidermal Cyst | 1 | 2025 | 5 | 0.980 |
Why?
|
| Molecular Docking Simulation | 2 | 2024 | 51 | 0.980 |
Why?
|
| Gliosarcoma | 2 | 2022 | 3 | 0.980 |
Why?
|
| Telomerase | 4 | 2021 | 37 | 0.970 |
Why?
|
| Reoperation | 7 | 2019 | 145 | 0.960 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2020 | 50 | 0.950 |
Why?
|
| Cysts | 1 | 2025 | 22 | 0.950 |
Why?
|
| Oligodendroglia | 1 | 2024 | 15 | 0.930 |
Why?
|
| Myelin Sheath | 1 | 2024 | 27 | 0.920 |
Why?
|
| Venous Thromboembolism | 4 | 2022 | 133 | 0.920 |
Why?
|
| Neuroendoscopy | 4 | 2020 | 14 | 0.900 |
Why?
|
| Genomics | 8 | 2019 | 123 | 0.890 |
Why?
|
| Spinal Neoplasms | 2 | 2022 | 39 | 0.880 |
Why?
|
| Cerebellar Neoplasms | 3 | 2015 | 28 | 0.860 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2021 | 20 | 0.860 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2020 | 5 | 0.830 |
Why?
|
| Adolescent | 22 | 2025 | 3122 | 0.830 |
Why?
|
| Precision Medicine | 3 | 2019 | 76 | 0.820 |
Why?
|
| Brain Diseases | 2 | 2018 | 36 | 0.810 |
Why?
|
| Astrocytoma | 5 | 2015 | 35 | 0.790 |
Why?
|
| Immunotherapy | 4 | 2019 | 161 | 0.770 |
Why?
|
| Microvascular Decompression Surgery | 2 | 2019 | 7 | 0.760 |
Why?
|
| Surgical Wound Infection | 5 | 2018 | 105 | 0.750 |
Why?
|
| Population Surveillance | 1 | 2021 | 86 | 0.720 |
Why?
|
| Anticoagulants | 5 | 2022 | 294 | 0.710 |
Why?
|
| Cerebrospinal Fluid Leak | 2 | 2018 | 14 | 0.710 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 29 | 0.710 |
Why?
|
| Labyrinth Diseases | 2 | 2019 | 3 | 0.700 |
Why?
|
| Brain Abscess | 4 | 2018 | 6 | 0.700 |
Why?
|
| DNA Modification Methylases | 1 | 2020 | 13 | 0.700 |
Why?
|
| DNA Repair Enzymes | 1 | 2020 | 9 | 0.700 |
Why?
|
| Neoplasms | 9 | 2019 | 809 | 0.690 |
Why?
|
| Length of Stay | 5 | 2019 | 229 | 0.690 |
Why?
|
| Warfarin | 2 | 2019 | 94 | 0.680 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 679 | 0.680 |
Why?
|
| Neuronavigation | 2 | 2018 | 9 | 0.670 |
Why?
|
| Paranasal Sinuses | 1 | 2020 | 6 | 0.670 |
Why?
|
| Prospective Studies | 10 | 2022 | 1248 | 0.660 |
Why?
|
| Pituitary Apoplexy | 2 | 2016 | 2 | 0.650 |
Why?
|
| Computed Tomography Angiography | 3 | 2018 | 24 | 0.640 |
Why?
|
| Enoxaparin | 1 | 2019 | 37 | 0.640 |
Why?
|
| Microsatellite Repeats | 1 | 2019 | 56 | 0.630 |
Why?
|
| Rhabdoid Tumor | 2 | 2017 | 9 | 0.630 |
Why?
|
| Intracranial Aneurysm | 2 | 2012 | 58 | 0.620 |
Why?
|
| Sphenoid Sinus | 2 | 2016 | 5 | 0.620 |
Why?
|
| Internship and Residency | 2 | 2021 | 239 | 0.620 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2016 | 13 | 0.620 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2019 | 31 | 0.620 |
Why?
|
| Epigenesis, Genetic | 3 | 2019 | 147 | 0.610 |
Why?
|
| Combined Modality Therapy | 11 | 2019 | 300 | 0.610 |
Why?
|
| Bone and Bones | 1 | 2019 | 75 | 0.610 |
Why?
|
| Salvage Therapy | 5 | 2019 | 34 | 0.570 |
Why?
|
| Signal Transduction | 11 | 2025 | 1435 | 0.570 |
Why?
|
| History, 20th Century | 8 | 2021 | 84 | 0.570 |
Why?
|
| Contact Lenses | 1 | 2017 | 6 | 0.570 |
Why?
|
| Gene Expression | 4 | 2016 | 417 | 0.570 |
Why?
|
| Printing, Three-Dimensional | 1 | 2018 | 31 | 0.560 |
Why?
|
| Keratitis | 1 | 2017 | 28 | 0.560 |
Why?
|
| Evidence-Based Medicine | 3 | 2021 | 145 | 0.560 |
Why?
|
| Tumor Microenvironment | 6 | 2025 | 178 | 0.550 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2017 | 66 | 0.550 |
Why?
|
| Proteins | 5 | 2024 | 252 | 0.550 |
Why?
|
| Pituitary Gland | 4 | 2023 | 53 | 0.550 |
Why?
|
| Semicircular Canals | 1 | 2017 | 1 | 0.540 |
Why?
|
| Thrombocytopenia | 2 | 2016 | 113 | 0.540 |
Why?
|
| Carcinogenesis | 1 | 2017 | 81 | 0.540 |
Why?
|
| Whole Exome Sequencing | 1 | 2016 | 9 | 0.530 |
Why?
|
| Chromosomes, Human | 1 | 2016 | 32 | 0.520 |
Why?
|
| Critical Care | 3 | 2015 | 49 | 0.520 |
Why?
|
| Serum Albumin | 1 | 2016 | 35 | 0.510 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 1319 | 0.510 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 19 | 0.510 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2015 | 120 | 0.510 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2016 | 11 | 0.500 |
Why?
|
| Age Factors | 8 | 2021 | 734 | 0.500 |
Why?
|
| Nose | 3 | 2023 | 23 | 0.500 |
Why?
|
| Recovery of Function | 1 | 2016 | 118 | 0.500 |
Why?
|
| United States | 13 | 2022 | 2146 | 0.500 |
Why?
|
| Neoplasm Grading | 11 | 2022 | 104 | 0.500 |
Why?
|
| Sphenoid Bone | 5 | 2017 | 8 | 0.500 |
Why?
|
| Microsurgery | 5 | 2020 | 45 | 0.500 |
Why?
|
| Infratentorial Neoplasms | 1 | 2015 | 4 | 0.490 |
Why?
|
| Pinealoma | 1 | 2015 | 4 | 0.490 |
Why?
|
| Preoperative Care | 2 | 2015 | 81 | 0.490 |
Why?
|
| Teratoma | 1 | 2015 | 17 | 0.490 |
Why?
|
| Ganglioglioma | 1 | 2015 | 4 | 0.480 |
Why?
|
| Registries | 4 | 2019 | 387 | 0.480 |
Why?
|
| DNA Mutational Analysis | 7 | 2016 | 94 | 0.480 |
Why?
|
| Tomography, Spiral Computed | 1 | 2015 | 8 | 0.480 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 40 | 0.480 |
Why?
|
| Animals | 26 | 2025 | 10423 | 0.480 |
Why?
|
| Athletic Injuries | 2 | 2006 | 120 | 0.480 |
Why?
|
| Cerebral Veins | 1 | 2015 | 11 | 0.480 |
Why?
|
| Medulla Oblongata | 1 | 2015 | 12 | 0.470 |
Why?
|
| Odontoid Process | 1 | 2015 | 12 | 0.470 |
Why?
|
| Cerebral Arteries | 1 | 2015 | 33 | 0.470 |
Why?
|
| Vision Disorders | 2 | 2014 | 38 | 0.460 |
Why?
|
| Operative Time | 4 | 2019 | 41 | 0.460 |
Why?
|
| Risk Factors | 12 | 2022 | 2081 | 0.460 |
Why?
|
| Basal Ganglia Diseases | 1 | 2014 | 3 | 0.460 |
Why?
|
| Rhizopus | 1 | 2014 | 3 | 0.450 |
Why?
|
| Mucormycosis | 1 | 2014 | 6 | 0.450 |
Why?
|
| Body Mass Index | 1 | 2016 | 399 | 0.450 |
Why?
|
| Facial Nerve | 1 | 2014 | 6 | 0.440 |
Why?
|
| Survival Rate | 10 | 2021 | 430 | 0.430 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 13 | 0.430 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2015 | 134 | 0.430 |
Why?
|
| Chickens | 4 | 2019 | 61 | 0.430 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2021 | 31 | 0.420 |
Why?
|
| Melioidosis | 1 | 2013 | 2 | 0.420 |
Why?
|
| Fellowships and Scholarships | 1 | 2013 | 39 | 0.420 |
Why?
|
| Logistic Models | 5 | 2017 | 407 | 0.420 |
Why?
|
| Headache | 3 | 2025 | 34 | 0.420 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2018 | 251 | 0.420 |
Why?
|
| Monitoring, Intraoperative | 4 | 2016 | 30 | 0.420 |
Why?
|
| Neuroimaging | 3 | 2019 | 87 | 0.420 |
Why?
|
| Tumor Burden | 4 | 2021 | 110 | 0.410 |
Why?
|
| Exome | 5 | 2016 | 30 | 0.410 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2023 | 6 | 0.400 |
Why?
|
| Genome, Human | 5 | 2018 | 69 | 0.400 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2017 | 16 | 0.400 |
Why?
|
| Otolaryngology | 1 | 2012 | 8 | 0.400 |
Why?
|
| Biomedical Research | 1 | 2013 | 97 | 0.400 |
Why?
|
| Disease Progression | 11 | 2025 | 473 | 0.390 |
Why?
|
| Hydrocephalus | 3 | 2025 | 52 | 0.390 |
Why?
|
| Cranial Irradiation | 5 | 2022 | 12 | 0.390 |
Why?
|
| Decompressive Craniectomy | 4 | 2017 | 6 | 0.390 |
Why?
|
| Immunohistochemistry | 6 | 2021 | 463 | 0.390 |
Why?
|
| Cerebrovascular Circulation | 4 | 2007 | 220 | 0.390 |
Why?
|
| Lumbar Vertebrae | 3 | 2010 | 125 | 0.390 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2023 | 31 | 0.380 |
Why?
|
| Follow-Up Studies | 13 | 2021 | 1013 | 0.380 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2018 | 474 | 0.380 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2021 | 60 | 0.370 |
Why?
|
| Reconstructive Surgical Procedures | 3 | 2018 | 72 | 0.370 |
Why?
|
| Histones | 2 | 2022 | 95 | 0.370 |
Why?
|
| Oligodendroglioma | 3 | 2024 | 9 | 0.370 |
Why?
|
| Medical Oncology | 2 | 2021 | 94 | 0.360 |
Why?
|
| Genome-Wide Association Study | 4 | 2016 | 234 | 0.360 |
Why?
|
| Head Injuries, Penetrating | 2 | 2015 | 4 | 0.350 |
Why?
|
| Mice | 15 | 2025 | 4654 | 0.350 |
Why?
|
| Incidence | 8 | 2022 | 562 | 0.350 |
Why?
|
| Carcinoma, Transitional Cell | 4 | 2023 | 55 | 0.350 |
Why?
|
| Pituitary ACTH Hypersecretion | 2 | 2021 | 3 | 0.340 |
Why?
|
| Sella Turcica | 4 | 2018 | 10 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 409 | 0.340 |
Why?
|
| Neurosurgeons | 3 | 2021 | 22 | 0.340 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2000 | 18 | 0.340 |
Why?
|
| Spinal Injuries | 2 | 2006 | 13 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2017 | 155 | 0.330 |
Why?
|
| Eye Foreign Bodies | 1 | 2009 | 1 | 0.320 |
Why?
|
| Angiography, Digital Subtraction | 3 | 2017 | 19 | 0.320 |
Why?
|
| Wood | 1 | 2009 | 10 | 0.320 |
Why?
|
| Orbit | 1 | 2009 | 8 | 0.320 |
Why?
|
| Survival Analysis | 4 | 2020 | 288 | 0.320 |
Why?
|
| Orbital Fractures | 1 | 2009 | 6 | 0.320 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 73 | 0.320 |
Why?
|
| beta Catenin | 4 | 2018 | 66 | 0.320 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2023 | 163 | 0.320 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2017 | 129 | 0.320 |
Why?
|
| Child | 9 | 2024 | 2242 | 0.310 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2017 | 109 | 0.300 |
Why?
|
| Stroke | 4 | 2017 | 252 | 0.300 |
Why?
|
| Hyponatremia | 2 | 2018 | 17 | 0.300 |
Why?
|
| Pulmonary Embolism | 2 | 2022 | 126 | 0.300 |
Why?
|
| Cohort Studies | 8 | 2022 | 887 | 0.300 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 971 | 0.300 |
Why?
|
| Time Factors | 8 | 2019 | 1592 | 0.290 |
Why?
|
| Chromosome Aberrations | 3 | 2016 | 37 | 0.290 |
Why?
|
| Oxygen Consumption | 2 | 2006 | 181 | 0.290 |
Why?
|
| Gene Expression Profiling | 9 | 2021 | 453 | 0.290 |
Why?
|
| Intraoperative Complications | 2 | 2012 | 47 | 0.290 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2018 | 14 | 0.280 |
Why?
|
| Embolization, Therapeutic | 3 | 2017 | 47 | 0.280 |
Why?
|
| Multimodal Imaging | 2 | 2019 | 22 | 0.280 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 135 | 0.280 |
Why?
|
| Neoplasm, Residual | 5 | 2016 | 31 | 0.280 |
Why?
|
| Ligands | 2 | 2024 | 176 | 0.280 |
Why?
|
| Decompression, Surgical | 3 | 2015 | 76 | 0.280 |
Why?
|
| Neurofibromatosis 1 | 1 | 2007 | 6 | 0.280 |
Why?
|
| Promoter Regions, Genetic | 6 | 2019 | 343 | 0.280 |
Why?
|
| Gene Dosage | 7 | 2017 | 35 | 0.270 |
Why?
|
| Prostheses and Implants | 2 | 2018 | 28 | 0.270 |
Why?
|
| Hypothalamic Neoplasms | 1 | 2007 | 1 | 0.270 |
Why?
|
| Preoperative Period | 2 | 2018 | 15 | 0.270 |
Why?
|
| DNA-Binding Proteins | 5 | 2018 | 490 | 0.270 |
Why?
|
| Corpus Callosum | 1 | 2007 | 20 | 0.270 |
Why?
|
| Cerebral Revascularization | 1 | 2006 | 11 | 0.260 |
Why?
|
| RNA, Messenger | 3 | 2017 | 659 | 0.260 |
Why?
|
| Carotid Stenosis | 1 | 2006 | 27 | 0.250 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2018 | 79 | 0.250 |
Why?
|
| SEER Program | 3 | 2021 | 47 | 0.250 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2021 | 29 | 0.250 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 57 | 0.250 |
Why?
|
| Skull Neoplasms | 2 | 2015 | 4 | 0.250 |
Why?
|
| Transcription Factors | 4 | 2015 | 520 | 0.250 |
Why?
|
| Disease Management | 2 | 2024 | 88 | 0.240 |
Why?
|
| Genetic Markers | 2 | 2015 | 93 | 0.240 |
Why?
|
| Biomarkers | 3 | 2021 | 765 | 0.240 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 414 | 0.240 |
Why?
|
| Molecular Imaging | 2 | 2016 | 35 | 0.240 |
Why?
|
| Optic Nerve | 2 | 2024 | 28 | 0.230 |
Why?
|
| Genes, Mitochondrial | 1 | 2024 | 10 | 0.230 |
Why?
|
| Myelin Proteins | 1 | 2024 | 13 | 0.230 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 1 | 2024 | 1 | 0.230 |
Why?
|
| Brain Ischemia | 3 | 2016 | 85 | 0.230 |
Why?
|
| Drug Discovery | 1 | 2024 | 34 | 0.230 |
Why?
|
| Cerebellopontine Angle | 2 | 2015 | 8 | 0.230 |
Why?
|
| Cation Transport Proteins | 1 | 2025 | 60 | 0.230 |
Why?
|
| Microglia | 1 | 2025 | 64 | 0.230 |
Why?
|
| Diagnosis, Differential | 5 | 2018 | 371 | 0.230 |
Why?
|
| Fetal Proteins | 1 | 2024 | 3 | 0.230 |
Why?
|
| Extracellular Vesicles | 1 | 2025 | 43 | 0.230 |
Why?
|
| T-Box Domain Proteins | 1 | 2024 | 8 | 0.230 |
Why?
|
| Transcriptome | 2 | 2017 | 214 | 0.230 |
Why?
|
| Mass Spectrometry | 2 | 2016 | 191 | 0.230 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 459 | 0.220 |
Why?
|
| Child Mortality | 1 | 2024 | 4 | 0.220 |
Why?
|
| Epilepsy | 1 | 2024 | 35 | 0.220 |
Why?
|
| Standard of Care | 1 | 2024 | 12 | 0.220 |
Why?
|
| Parkinson Disease | 1 | 2024 | 46 | 0.220 |
Why?
|
| Ventriculoperitoneal Shunt | 2 | 2016 | 26 | 0.220 |
Why?
|
| Brain Stem Neoplasms | 2 | 2015 | 12 | 0.220 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 282 | 0.220 |
Why?
|
| Autopsy | 2 | 2024 | 25 | 0.210 |
Why?
|
| Databases, Factual | 4 | 2021 | 253 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2021 | 103 | 0.210 |
Why?
|
| Oncogenes | 2 | 2017 | 34 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 140 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2016 | 135 | 0.210 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 226 | 0.210 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 68 | 0.210 |
Why?
|
| Dacarbazine | 2 | 2015 | 15 | 0.210 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2015 | 21 | 0.210 |
Why?
|
| Hydrocortisone | 2 | 2021 | 89 | 0.210 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2013 | 71 | 0.210 |
Why?
|
| Ureter | 1 | 2023 | 8 | 0.210 |
Why?
|
| Ureteral Neoplasms | 1 | 2023 | 6 | 0.210 |
Why?
|
| Electroencephalography | 1 | 2024 | 136 | 0.200 |
Why?
|
| Diskectomy | 2 | 2015 | 21 | 0.200 |
Why?
|
| Tuberculosis | 1 | 2023 | 25 | 0.200 |
Why?
|
| Genotype | 2 | 2022 | 456 | 0.200 |
Why?
|
| Dura Mater | 2 | 2020 | 11 | 0.200 |
Why?
|
| Carotid Artery, Internal | 2 | 2017 | 19 | 0.200 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 247 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2019 | 113 | 0.200 |
Why?
|
| Ozone | 1 | 2022 | 5 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2023 | 77 | 0.190 |
Why?
|
| B-Lymphocytes | 3 | 2001 | 283 | 0.190 |
Why?
|
| Curriculum | 2 | 2021 | 291 | 0.190 |
Why?
|
| Particulate Matter | 1 | 2022 | 17 | 0.190 |
Why?
|
| Sex Factors | 3 | 2021 | 466 | 0.190 |
Why?
|
| Radiation Oncology | 1 | 2022 | 19 | 0.190 |
Why?
|
| Neurovascular Coupling | 1 | 2024 | 154 | 0.190 |
Why?
|
| Antithrombin III Deficiency | 1 | 2021 | 6 | 0.190 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 478 | 0.190 |
Why?
|
| Child Health | 1 | 2022 | 17 | 0.190 |
Why?
|
| Pandemics | 2 | 2020 | 186 | 0.190 |
Why?
|
| Neoplasm Proteins | 2 | 2015 | 123 | 0.190 |
Why?
|
| Endopeptidases | 2 | 2018 | 20 | 0.190 |
Why?
|
| Glycine | 1 | 2022 | 31 | 0.190 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 101 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2015 | 14 | 0.190 |
Why?
|
| Cell Line | 5 | 2019 | 696 | 0.190 |
Why?
|
| Cadaver | 2 | 2020 | 57 | 0.190 |
Why?
|
| Physicians, Women | 1 | 2021 | 7 | 0.180 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2000 | 24 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 2 | 2012 | 149 | 0.180 |
Why?
|
| Intracranial Hemorrhages | 3 | 2016 | 30 | 0.180 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 98 | 0.180 |
Why?
|
| Genes, cdc | 1 | 2021 | 7 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2022 | 65 | 0.180 |
Why?
|
| MutS Proteins | 1 | 2021 | 1 | 0.180 |
Why?
|
| Comparative Genomic Hybridization | 6 | 2016 | 21 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 4 | 2016 | 524 | 0.180 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 474 | 0.180 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2021 | 33 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 97 | 0.180 |
Why?
|
| Growth Substances | 1 | 2000 | 11 | 0.180 |
Why?
|
| CD40 Antigens | 1 | 2000 | 14 | 0.170 |
Why?
|
| Sensitivity and Specificity | 3 | 2023 | 521 | 0.170 |
Why?
|
| Universities | 1 | 2021 | 120 | 0.170 |
Why?
|
| Spinal Diseases | 1 | 2021 | 43 | 0.170 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 45 | 0.170 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2020 | 2 | 0.170 |
Why?
|
| GATA2 Transcription Factor | 1 | 2020 | 3 | 0.170 |
Why?
|
| Spine | 1 | 2021 | 61 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2020 | 31 | 0.170 |
Why?
|
| Insurance, Health | 1 | 2020 | 51 | 0.170 |
Why?
|
| Thrombosis | 2 | 2021 | 149 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 214 | 0.170 |
Why?
|
| Neurofibromin 2 | 2 | 2017 | 3 | 0.170 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 34 | 0.170 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 40 | 0.170 |
Why?
|
| Hospitals | 1 | 2020 | 77 | 0.170 |
Why?
|
| Aneurysm | 2 | 2013 | 25 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 3 | 2019 | 330 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 39 | 0.160 |
Why?
|
| Aneurysm, False | 2 | 2017 | 19 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 108 | 0.160 |
Why?
|
| Frontal Bone | 2 | 2016 | 5 | 0.160 |
Why?
|
| Collagen | 2 | 2016 | 156 | 0.160 |
Why?
|
| Quinolines | 1 | 2019 | 25 | 0.160 |
Why?
|
| Risk | 1 | 2019 | 137 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.160 |
Why?
|
| Brachytherapy | 1 | 2019 | 51 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.160 |
Why?
|
| Cell Proliferation | 4 | 2017 | 806 | 0.160 |
Why?
|
| Iatrogenic Disease | 1 | 2019 | 14 | 0.160 |
Why?
|
| Aminopyridines | 1 | 2019 | 7 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2019 | 8 | 0.160 |
Why?
|
| Morpholines | 1 | 2019 | 28 | 0.150 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2015 | 12 | 0.150 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2018 | 7 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 190 | 0.150 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2019 | 94 | 0.150 |
Why?
|
| Intervertebral Disc Displacement | 2 | 2010 | 10 | 0.150 |
Why?
|
| Biopsy | 2 | 2017 | 206 | 0.150 |
Why?
|
| Morbidity | 1 | 2018 | 58 | 0.150 |
Why?
|
| Receptor, ErbB-2 | 3 | 2019 | 33 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2019 | 53 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 12 | 0.150 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2018 | 7 | 0.150 |
Why?
|
| Leiomyosarcoma | 1 | 2017 | 10 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2016 | 63 | 0.140 |
Why?
|
| Neurologic Examination | 2 | 2015 | 21 | 0.140 |
Why?
|
| Models, Anatomic | 1 | 2018 | 25 | 0.140 |
Why?
|
| Cranial Fossa, Posterior | 2 | 2017 | 5 | 0.140 |
Why?
|
| Orbital Neoplasms | 1 | 2017 | 11 | 0.140 |
Why?
|
| Semantics | 1 | 2017 | 11 | 0.140 |
Why?
|
| Re-Irradiation | 1 | 2017 | 2 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2018 | 24 | 0.140 |
Why?
|
| Macrophages | 1 | 2020 | 295 | 0.140 |
Why?
|
| Chromogranins | 1 | 2017 | 2 | 0.140 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2017 | 2 | 0.140 |
Why?
|
| History, 21st Century | 2 | 2020 | 49 | 0.140 |
Why?
|
| Spondylolysis | 2 | 2008 | 3 | 0.140 |
Why?
|
| Brain Injuries | 2 | 2015 | 49 | 0.140 |
Why?
|
| Trans-Activators | 2 | 2013 | 118 | 0.140 |
Why?
|
| Prosthesis Design | 1 | 2017 | 87 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 46 | 0.140 |
Why?
|
| Hematoma, Epidural, Spinal | 2 | 2008 | 9 | 0.140 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 71 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 243 | 0.140 |
Why?
|
| RNA Interference | 4 | 2010 | 137 | 0.140 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2017 | 7 | 0.140 |
Why?
|
| Carotid Artery Injuries | 1 | 2017 | 12 | 0.140 |
Why?
|
| Bevacizumab | 1 | 2017 | 103 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 42 | 0.140 |
Why?
|
| Gonadotrophs | 1 | 2016 | 3 | 0.140 |
Why?
|
| Down-Regulation | 1 | 2017 | 199 | 0.140 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 237 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 82 | 0.130 |
Why?
|
| Base Sequence | 5 | 2014 | 586 | 0.130 |
Why?
|
| Autophagy | 1 | 2017 | 73 | 0.130 |
Why?
|
| Spinal Fractures | 2 | 2008 | 41 | 0.130 |
Why?
|
| Vestibule, Labyrinth | 1 | 2016 | 2 | 0.130 |
Why?
|
| Ear Neoplasms | 1 | 2016 | 4 | 0.130 |
Why?
|
| Cavernous Sinus | 1 | 2016 | 5 | 0.130 |
Why?
|
| INDEL Mutation | 1 | 2016 | 7 | 0.130 |
Why?
|
| Fatal Outcome | 2 | 2014 | 67 | 0.130 |
Why?
|
| Hydrocephalus, Normal Pressure | 1 | 2016 | 3 | 0.130 |
Why?
|
| Wnt Signaling Pathway | 1 | 2017 | 57 | 0.130 |
Why?
|
| Ki-67 Antigen | 1 | 2016 | 23 | 0.130 |
Why?
|
| Neurilemmoma | 1 | 2016 | 13 | 0.130 |
Why?
|
| Visual Fields | 1 | 2016 | 33 | 0.130 |
Why?
|
| Aftercare | 1 | 2016 | 33 | 0.130 |
Why?
|
| Radiography | 6 | 2022 | 202 | 0.130 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2016 | 9 | 0.130 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2016 | 2 | 0.130 |
Why?
|
| Surgical Mesh | 1 | 2016 | 14 | 0.130 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2016 | 2 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2017 | 104 | 0.130 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2016 | 7 | 0.130 |
Why?
|
| Necrosis | 2 | 2015 | 85 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2008 | 138 | 0.130 |
Why?
|
| Meningitis, Bacterial | 1 | 2016 | 9 | 0.130 |
Why?
|
| Titanium | 1 | 2016 | 37 | 0.130 |
Why?
|
| Intracranial Hypotension | 1 | 2016 | 6 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2016 | 68 | 0.130 |
Why?
|
| Intracranial Pressure | 2 | 2006 | 11 | 0.130 |
Why?
|
| History, 19th Century | 3 | 2015 | 36 | 0.130 |
Why?
|
| Lumbosacral Region | 1 | 2016 | 20 | 0.130 |
Why?
|
| Needles | 1 | 2016 | 26 | 0.130 |
Why?
|
| Myocutaneous Flap | 1 | 2015 | 3 | 0.120 |
Why?
|
| Hemifacial Spasm | 1 | 2015 | 2 | 0.120 |
Why?
|
| Psychosurgery | 1 | 2015 | 3 | 0.120 |
Why?
|
| Endocrine Surgical Procedures | 1 | 2015 | 1 | 0.120 |
Why?
|
| Pituitary Diseases | 1 | 2015 | 5 | 0.120 |
Why?
|
| Cranial Nerves | 1 | 2015 | 6 | 0.120 |
Why?
|
| Liability, Legal | 1 | 2015 | 5 | 0.120 |
Why?
|
| Famous Persons | 1 | 2015 | 4 | 0.120 |
Why?
|
| Malpractice | 1 | 2015 | 6 | 0.120 |
Why?
|
| Free Tissue Flaps | 1 | 2015 | 5 | 0.120 |
Why?
|
| SMARCB1 Protein | 1 | 2015 | 5 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 5 | 2016 | 369 | 0.120 |
Why?
|
| Trigeminal Neuralgia | 1 | 2015 | 13 | 0.120 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2015 | 14 | 0.120 |
Why?
|
| Cochlear Nerve | 1 | 2015 | 1 | 0.120 |
Why?
|
| Computer Systems | 1 | 2015 | 9 | 0.120 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2015 | 3 | 0.120 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 14 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 95 | 0.120 |
Why?
|
| American Civil War | 1 | 2015 | 1 | 0.120 |
Why?
|
| Health Care Reform | 1 | 2015 | 13 | 0.120 |
Why?
|
| Meat | 1 | 2015 | 14 | 0.120 |
Why?
|
| Head Protective Devices | 1 | 2015 | 6 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 37 | 0.120 |
Why?
|
| Pons | 1 | 2015 | 7 | 0.120 |
Why?
|
| Baseball | 1 | 2015 | 10 | 0.120 |
Why?
|
| Alcoholism | 1 | 2016 | 119 | 0.120 |
Why?
|
| Computational Biology | 1 | 2016 | 155 | 0.120 |
Why?
|
| Platelet Count | 1 | 2016 | 111 | 0.120 |
Why?
|
| Phlebography | 1 | 2015 | 20 | 0.120 |
Why?
|
| Scalp | 1 | 2015 | 14 | 0.120 |
Why?
|
| Gene Silencing | 1 | 2015 | 65 | 0.120 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 55 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 21 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2017 | 28 | 0.120 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 55 | 0.120 |
Why?
|
| Comorbidity | 1 | 2016 | 258 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2016 | 167 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 112 | 0.120 |
Why?
|
| Temporal Lobe | 1 | 2015 | 32 | 0.120 |
Why?
|
| Overweight | 1 | 2016 | 113 | 0.120 |
Why?
|
| Cerebellum | 1 | 2015 | 41 | 0.120 |
Why?
|
| Feeding Behavior | 1 | 2016 | 102 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 96 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 44 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 547 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 10 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 267 | 0.120 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 769 | 0.120 |
Why?
|
| Brain Concussion | 1 | 2015 | 48 | 0.120 |
Why?
|
| Blood Pressure | 2 | 2006 | 354 | 0.120 |
Why?
|
| Epistaxis | 1 | 2014 | 7 | 0.110 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 49 | 0.110 |
Why?
|
| Glutarates | 1 | 2014 | 3 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 45 | 0.110 |
Why?
|
| Cell Lineage | 1 | 2014 | 51 | 0.110 |
Why?
|
| Mental Disorders | 1 | 2015 | 110 | 0.110 |
Why?
|
| Molecular Sequence Data | 5 | 2014 | 1054 | 0.110 |
Why?
|
| Thermodynamics | 1 | 2014 | 93 | 0.110 |
Why?
|
| Intraoperative Care | 1 | 2014 | 22 | 0.110 |
Why?
|
| Models, Chemical | 1 | 2014 | 90 | 0.110 |
Why?
|
| Oviposition | 1 | 2014 | 4 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2014 | 68 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2015 | 193 | 0.110 |
Why?
|
| Germ-Line Mutation | 2 | 2017 | 30 | 0.110 |
Why?
|
| Regional Blood Flow | 1 | 2015 | 163 | 0.110 |
Why?
|
| Basal Ganglia Cerebrovascular Disease | 1 | 2013 | 1 | 0.110 |
Why?
|
| Histocytochemistry | 1 | 2013 | 20 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 385 | 0.110 |
Why?
|
| Mastoid | 1 | 2013 | 2 | 0.110 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2013 | 9 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 105 | 0.110 |
Why?
|
| Hospitalization | 1 | 2015 | 198 | 0.110 |
Why?
|
| Thienamycins | 1 | 2013 | 1 | 0.110 |
Why?
|
| Burkholderia pseudomallei | 1 | 2013 | 3 | 0.110 |
Why?
|
| Cambodia | 1 | 2013 | 10 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 144 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 356 | 0.100 |
Why?
|
| Abscess | 1 | 2013 | 24 | 0.100 |
Why?
|
| Infant | 4 | 2022 | 1004 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 183 | 0.100 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2012 | 4 | 0.100 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2012 | 5 | 0.100 |
Why?
|
| Algorithms | 1 | 2015 | 430 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 77 | 0.100 |
Why?
|
| TNF Receptor-Associated Factor 1 | 3 | 2001 | 5 | 0.100 |
Why?
|
| Body Fluids | 1 | 2011 | 18 | 0.090 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2011 | 1 | 0.090 |
Why?
|
| Arteries | 2 | 2013 | 65 | 0.090 |
Why?
|
| Surgical Instruments | 2 | 2015 | 15 | 0.090 |
Why?
|
| Lymphocyte Activation | 3 | 2001 | 209 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2010 | 4 | 0.090 |
Why?
|
| Retinoblastoma Protein | 1 | 2010 | 10 | 0.090 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2012 | 59 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2010 | 9 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 224 | 0.080 |
Why?
|
| Introns | 2 | 2000 | 43 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 961 | 0.080 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2009 | 3 | 0.080 |
Why?
|
| Genes, ras | 1 | 2009 | 12 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2001 | 247 | 0.080 |
Why?
|
| Cranial Fossa, Middle | 1 | 2009 | 2 | 0.080 |
Why?
|
| Chromosome Mapping | 2 | 2000 | 130 | 0.080 |
Why?
|
| Cerebral Hemorrhage | 1 | 2010 | 91 | 0.080 |
Why?
|
| Optic Nerve Injuries | 1 | 2009 | 4 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2021 | 67 | 0.080 |
Why?
|
| Therapeutic Irrigation | 1 | 2009 | 19 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 194 | 0.080 |
Why?
|
| Blindness | 1 | 2009 | 34 | 0.080 |
Why?
|
| ras Proteins | 1 | 2009 | 43 | 0.080 |
Why?
|
| Intraocular Pressure | 1 | 2009 | 62 | 0.080 |
Why?
|
| Tissue Distribution | 2 | 2019 | 137 | 0.080 |
Why?
|
| Genes, p53 | 1 | 2009 | 14 | 0.080 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2008 | 18 | 0.080 |
Why?
|
| Sarcoma | 2 | 2024 | 29 | 0.070 |
Why?
|
| Hemostasis | 2 | 2021 | 48 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2000 | 632 | 0.070 |
Why?
|
| ErbB Receptors | 2 | 2021 | 100 | 0.070 |
Why?
|
| Transcription, Genetic | 3 | 2012 | 403 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2018 | 1146 | 0.070 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 8 | 0.070 |
Why?
|
| Exons | 2 | 2014 | 42 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2007 | 38 | 0.070 |
Why?
|
| Neural Tube Defects | 1 | 2007 | 20 | 0.070 |
Why?
|
| Temporal Arteries | 1 | 2007 | 3 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 97 | 0.070 |
Why?
|
| Phenytoin | 1 | 2007 | 15 | 0.070 |
Why?
|
| Physician's Role | 1 | 2006 | 29 | 0.070 |
Why?
|
| Craniocerebral Trauma | 1 | 2006 | 27 | 0.070 |
Why?
|
| Inpatients | 2 | 2017 | 56 | 0.060 |
Why?
|
| Hearing | 2 | 2018 | 28 | 0.060 |
Why?
|
| Middle Cerebral Artery | 1 | 2006 | 48 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2017 | 147 | 0.060 |
Why?
|
| Propensity Score | 2 | 2017 | 54 | 0.060 |
Why?
|
| Microdialysis | 1 | 2006 | 2 | 0.060 |
Why?
|
| Oximetry | 1 | 2006 | 10 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 1461 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 433 | 0.060 |
Why?
|
| Football | 1 | 2006 | 71 | 0.060 |
Why?
|
| Recurrence | 2 | 2021 | 322 | 0.060 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2015 | 33 | 0.060 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2025 | 6 | 0.060 |
Why?
|
| Ophthalmic Artery | 1 | 2005 | 3 | 0.060 |
Why?
|
| Alleles | 3 | 2013 | 350 | 0.060 |
Why?
|
| Awareness | 1 | 2005 | 16 | 0.060 |
Why?
|
| Vision, Ocular | 1 | 2005 | 27 | 0.060 |
Why?
|
| Gene Amplification | 4 | 2008 | 22 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 452 | 0.060 |
Why?
|
| Karnofsky Performance Status | 2 | 2015 | 15 | 0.060 |
Why?
|
| Smoothened Receptor | 2 | 2016 | 8 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 1 | 2025 | 97 | 0.060 |
Why?
|
| Zinc | 1 | 2025 | 63 | 0.060 |
Why?
|
| Protein Domains | 1 | 2024 | 52 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 607 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2019 | 267 | 0.060 |
Why?
|
| Brain Edema | 2 | 2015 | 21 | 0.060 |
Why?
|
| South Africa | 1 | 2024 | 19 | 0.060 |
Why?
|
| Stillbirth | 1 | 2024 | 15 | 0.060 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 3 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2019 | 189 | 0.050 |
Why?
|
| Cause of Death | 1 | 2024 | 73 | 0.050 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2024 | 74 | 0.050 |
Why?
|
| Cell Survival | 3 | 2009 | 409 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2015 | 242 | 0.050 |
Why?
|
| Phenotype | 2 | 2016 | 681 | 0.050 |
Why?
|
| Sputum | 1 | 2023 | 8 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2016 | 15 | 0.050 |
Why?
|
| Scotland | 1 | 2023 | 5 | 0.050 |
Why?
|
| Bioreactors | 1 | 2003 | 38 | 0.050 |
Why?
|
| Reading | 1 | 2023 | 18 | 0.050 |
Why?
|
| Computers | 1 | 2023 | 30 | 0.050 |
Why?
|
| X-Rays | 1 | 2023 | 31 | 0.050 |
Why?
|
| Organoids | 1 | 2023 | 21 | 0.050 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 8 | 0.050 |
Why?
|
| Genes, myc | 1 | 2002 | 9 | 0.050 |
Why?
|
| Aggression | 1 | 2023 | 26 | 0.050 |
Why?
|
| Triage | 1 | 2023 | 33 | 0.050 |
Why?
|
| Models, Biological | 2 | 2007 | 466 | 0.050 |
Why?
|
| Protein Binding | 1 | 2024 | 658 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2002 | 38 | 0.050 |
Why?
|
| Societies | 1 | 2022 | 9 | 0.050 |
Why?
|
| World Health Organization | 1 | 2022 | 12 | 0.050 |
Why?
|
| Stem Cells | 1 | 2003 | 121 | 0.050 |
Why?
|
| Ultrasonography, Doppler | 1 | 2022 | 22 | 0.050 |
Why?
|
| Zambia | 1 | 2022 | 3 | 0.050 |
Why?
|
| Ohio | 1 | 2022 | 9 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 1999 | 208 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2022 | 9 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 14 | 0.050 |
Why?
|
| Mechanical Phenomena | 1 | 2022 | 21 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 39 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 16 | 0.050 |
Why?
|
| Consensus | 1 | 2021 | 75 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 63 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 34 | 0.050 |
Why?
|
| Learning Curve | 1 | 2021 | 13 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 35 | 0.050 |
Why?
|
| Mutation, Missense | 2 | 2014 | 69 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2022 | 104 | 0.050 |
Why?
|
| Lipopolysaccharides | 2 | 2000 | 157 | 0.050 |
Why?
|
| Radiation Exposure | 1 | 2021 | 17 | 0.050 |
Why?
|
| Pedicle Screws | 1 | 2021 | 13 | 0.040 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 1 | 2021 | 2 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2022 | 117 | 0.040 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2021 | 17 | 0.040 |
Why?
|
| Endothelium, Vascular | 2 | 2001 | 325 | 0.040 |
Why?
|
| Remission Induction | 1 | 2021 | 53 | 0.040 |
Why?
|
| Career Choice | 1 | 2021 | 53 | 0.040 |
Why?
|
| Transforming Growth Factors | 1 | 2000 | 2 | 0.040 |
Why?
|
| Receptors, Growth Factor | 1 | 2000 | 7 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 179 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 225 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 14 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2000 | 23 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2000 | 26 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2000 | 23 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2024 | 885 | 0.040 |
Why?
|
| Sp1 Transcription Factor | 1 | 2000 | 17 | 0.040 |
Why?
|
| Mass Screening | 1 | 2022 | 152 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 67 | 0.040 |
Why?
|
| Surgeons | 1 | 2021 | 50 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2021 | 76 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 60 | 0.040 |
Why?
|
| Cell Movement | 1 | 2022 | 373 | 0.040 |
Why?
|
| Medicaid | 1 | 2020 | 54 | 0.040 |
Why?
|
| Workload | 1 | 2020 | 38 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2001 | 109 | 0.040 |
Why?
|
| Seizures | 2 | 2012 | 48 | 0.040 |
Why?
|
| Health Personnel | 1 | 2020 | 95 | 0.040 |
Why?
|
| NIH 3T3 Cells | 2 | 2010 | 44 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1191 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 69 | 0.040 |
Why?
|
| Restriction Mapping | 1 | 1999 | 22 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2001 | 202 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 612 | 0.040 |
Why?
|
| Otologic Surgical Procedures | 1 | 2019 | 4 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1999 | 7 | 0.040 |
Why?
|
| Sex Chromosomes | 1 | 1999 | 2 | 0.040 |
Why?
|
| Breast | 1 | 2019 | 52 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2004 | 75 | 0.040 |
Why?
|
| Hyperprolactinemia | 1 | 2018 | 1 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 1998 | 12 | 0.040 |
Why?
|
| Hypothyroidism | 1 | 2018 | 11 | 0.040 |
Why?
|
| Hypopituitarism | 1 | 2018 | 5 | 0.040 |
Why?
|
| GTP-Binding Proteins | 1 | 1998 | 46 | 0.040 |
Why?
|
| Bone Cements | 1 | 2018 | 8 | 0.040 |
Why?
|
| Shock, Septic | 1 | 1998 | 38 | 0.040 |
Why?
|
| Kinetics | 2 | 2014 | 545 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 194 | 0.040 |
Why?
|
| Steroids | 1 | 2018 | 54 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2013 | 331 | 0.030 |
Why?
|
| Meningeal Arteries | 1 | 2017 | 3 | 0.030 |
Why?
|
| Gadolinium | 1 | 2017 | 6 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 19 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 162 | 0.030 |
Why?
|
| Hypophysectomy | 1 | 2016 | 4 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 99 | 0.030 |
Why?
|
| High-Temperature Requirement A Serine Peptidase 1 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2016 | 1 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2016 | 26 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2016 | 18 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2016 | 24 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 61 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 49 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2016 | 31 | 0.030 |
Why?
|
| Knee Prosthesis | 1 | 1996 | 6 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2016 | 71 | 0.030 |
Why?
|
| Hip Prosthesis | 1 | 1996 | 11 | 0.030 |
Why?
|
| Bandages | 1 | 1996 | 14 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 1996 | 51 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 39 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 58 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 112 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2016 | 41 | 0.030 |
Why?
|
| Stents | 1 | 2017 | 120 | 0.030 |
Why?
|
| Blood Patch, Epidural | 1 | 2016 | 2 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 2016 | 11 | 0.030 |
Why?
|
| Transplant Donor Site | 1 | 2015 | 1 | 0.030 |
Why?
|
| Superficial Back Muscles | 1 | 2015 | 1 | 0.030 |
Why?
|
| Parietal Bone | 1 | 2015 | 2 | 0.030 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2015 | 4 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2015 | 3 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2015 | 3 | 0.030 |
Why?
|
| Cholangiocarcinoma | 1 | 2015 | 5 | 0.030 |
Why?
|
| Oximes | 1 | 2015 | 8 | 0.030 |
Why?
|
| Valine | 1 | 2015 | 12 | 0.030 |
Why?
|
| Frontal Sinus | 1 | 2015 | 4 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 7 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2015 | 16 | 0.030 |
Why?
|
| Untranslated Regions | 1 | 2015 | 2 | 0.030 |
Why?
|
| RNA Splice Sites | 1 | 2015 | 6 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 31 | 0.030 |
Why?
|
| CpG Islands | 1 | 2015 | 26 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 67 | 0.030 |
Why?
|
| Homicide | 1 | 2015 | 7 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2015 | 51 | 0.030 |
Why?
|
| Nervous System Malformations | 1 | 2015 | 1 | 0.030 |
Why?
|
| Drainage | 1 | 2015 | 45 | 0.030 |
Why?
|
| Pyridones | 1 | 2015 | 35 | 0.030 |
Why?
|
| Imidazoles | 1 | 2015 | 63 | 0.030 |
Why?
|
| Neoplasm Seeding | 1 | 2015 | 1 | 0.030 |
Why?
|
| Cranial Nerve Injuries | 1 | 2015 | 1 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2015 | 10 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 51 | 0.030 |
Why?
|
| Neuroendocrine Tumors | 1 | 2015 | 29 | 0.030 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 497 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 125 | 0.030 |
Why?
|
| Wounds, Gunshot | 1 | 2015 | 18 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 269 | 0.030 |
Why?
|
| Selection Bias | 1 | 2015 | 13 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2015 | 103 | 0.030 |
Why?
|
| Translocation, Genetic | 2 | 2009 | 23 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2015 | 52 | 0.030 |
Why?
|
| X-linked Nuclear Protein | 1 | 2014 | 4 | 0.030 |
Why?
|
| Quantum Theory | 1 | 2014 | 22 | 0.030 |
Why?
|
| Static Electricity | 1 | 2014 | 35 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2014 | 46 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 133 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 1576 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 156 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 302 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 328 | 0.030 |
Why?
|
| Human T-lymphotropic virus 2 | 1 | 1994 | 1 | 0.030 |
Why?
|
| Deltaretrovirus Antibodies | 1 | 1994 | 1 | 0.030 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1994 | 4 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2014 | 52 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 167 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2004 | 15 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2014 | 100 | 0.030 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 70 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2013 | 46 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 163 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 514 | 0.030 |
Why?
|
| Plasmalogens | 1 | 2013 | 1 | 0.030 |
Why?
|
| Multigene Family | 1 | 2013 | 51 | 0.030 |
Why?
|
| Cognition | 1 | 2016 | 324 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 2013 | 14 | 0.030 |
Why?
|
| Phosphatidylserines | 1 | 2013 | 20 | 0.030 |
Why?
|
| Medical Errors | 1 | 2012 | 9 | 0.030 |
Why?
|
| Phosphatidylinositols | 1 | 2013 | 25 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2013 | 128 | 0.020 |
Why?
|
| Survival | 1 | 2012 | 3 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 284 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2012 | 57 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2012 | 18 | 0.020 |
Why?
|
| Brain Stem | 1 | 2012 | 23 | 0.020 |
Why?
|
| Apoptosis | 2 | 2009 | 775 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2012 | 28 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 39 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2011 | 7 | 0.020 |
Why?
|
| Hypertension | 1 | 2014 | 308 | 0.020 |
Why?
|
| African Americans | 1 | 1994 | 352 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 666 | 0.020 |
Why?
|
| Optic Nerve Diseases | 1 | 2011 | 16 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 636 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 199 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2011 | 111 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 34 | 0.020 |
Why?
|
| Renal Dialysis | 2 | 1983 | 52 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 90 | 0.020 |
Why?
|
| Dyskinesias | 1 | 2010 | 1 | 0.020 |
Why?
|
| Reflex, Abnormal | 1 | 2010 | 2 | 0.020 |
Why?
|
| Phloroglucinol | 1 | 2010 | 4 | 0.020 |
Why?
|
| Perceptual Disorders | 1 | 2010 | 4 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2009 | 3 | 0.020 |
Why?
|
| Genes, Lethal | 1 | 2009 | 6 | 0.020 |
Why?
|
| Piperazines | 1 | 2010 | 47 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2009 | 35 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 124 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2009 | 8 | 0.020 |
Why?
|
| Pyridines | 1 | 2010 | 107 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 540 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 722 | 0.020 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2009 | 1 | 0.020 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2009 | 2 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 250 | 0.020 |
Why?
|
| Indoles | 1 | 2010 | 99 | 0.020 |
Why?
|
| Transfection | 2 | 2001 | 318 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 8 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Pedigree | 1 | 2009 | 155 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 103 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 23 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2001 | 985 | 0.020 |
Why?
|
| Microsatellite Instability | 1 | 2007 | 10 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 2010 | 146 | 0.020 |
Why?
|
| Gene Library | 1 | 2007 | 45 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 44 | 0.020 |
Why?
|
| Genome | 1 | 2007 | 56 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2007 | 64 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2007 | 191 | 0.020 |
Why?
|
| Heart Valve Prosthesis | 1 | 2006 | 62 | 0.020 |
Why?
|
| Vision Tests | 1 | 2005 | 3 | 0.020 |
Why?
|
| Angiography | 1 | 2005 | 35 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2004 | 12 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2004 | 21 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1983 | 45 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2004 | 144 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2002 | 14 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2002 | 34 | 0.010 |
Why?
|
| Superantigens | 1 | 2001 | 6 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2001 | 23 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2001 | 34 | 0.010 |
Why?
|
| Skin Diseases | 1 | 2001 | 29 | 0.010 |
Why?
|
| Endostatins | 1 | 2001 | 3 | 0.010 |
Why?
|
| Capsules | 1 | 2001 | 8 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 2001 | 10 | 0.010 |
Why?
|
| Alginates | 1 | 2001 | 14 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2001 | 46 | 0.010 |
Why?
|
| Polylysine | 1 | 2001 | 14 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 78 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2001 | 60 | 0.010 |
Why?
|
| Capillaries | 1 | 2001 | 33 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 129 | 0.010 |
Why?
|
| CREB-Binding Protein | 1 | 2000 | 10 | 0.010 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2000 | 13 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2000 | 18 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2001 | 116 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2001 | 59 | 0.010 |
Why?
|
| Microcirculation | 1 | 2001 | 112 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2001 | 95 | 0.010 |
Why?
|
| Swine | 1 | 2001 | 236 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 413 | 0.010 |
Why?
|
| Sex Determination Processes | 1 | 1999 | 2 | 0.010 |
Why?
|
| Sex-Determining Region Y Protein | 1 | 1999 | 5 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 388 | 0.010 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1998 | 5 | 0.010 |
Why?
|
| Wasp Venoms | 1 | 1998 | 2 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1999 | 82 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 133 | 0.010 |
Why?
|
| Testis | 1 | 1999 | 39 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2001 | 848 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1998 | 82 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1998 | 233 | 0.010 |
Why?
|
| Monocytes | 1 | 1998 | 135 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1976 | 28 | 0.010 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 1976 | 25 | 0.010 |
Why?
|
| Peptides | 1 | 1998 | 288 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1996 | 145 | 0.010 |
Why?
|
| Rats | 1 | 1998 | 1576 | 0.010 |
Why?
|
| New York | 1 | 1994 | 17 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1994 | 77 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 2 | 1983 | 69 | 0.010 |
Why?
|
| Femoral Vein | 1 | 1976 | 13 | 0.000 |
Why?
|
| Polyethylene Terephthalates | 1 | 1976 | 7 | 0.000 |
Why?
|
| Veins | 1 | 1976 | 19 | 0.000 |
Why?
|
| Hematoma | 1 | 1976 | 26 | 0.000 |
Why?
|
| Brachial Artery | 1 | 1976 | 36 | 0.000 |
Why?
|
| Arm | 1 | 1976 | 37 | 0.000 |
Why?
|
| Femoral Artery | 1 | 1976 | 58 | 0.000 |
Why?
|
| Dogs | 1 | 1976 | 509 | 0.000 |
Why?
|